NanoViricides, Inc. (NNVC)
USD 0.99
(-4.81%)
USD 0.99
(-4.81%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -8.51 Million USD | 4.78% |
| 2023 | -8.94 Million USD | -10.23% |
| 2022 | -8.11 Million USD | 7.21% |
| 2021 | -8.74 Million USD | -9.35% |
| 2020 | -7.99 Million USD | 7.66% |
| 2019 | -8.65 Million USD | 7.14% |
| 2018 | -9.32 Million USD | 2.87% |
| 2017 | -9.6 Million USD | -8.37% |
| 2016 | -8.85 Million USD | -25.43% |
| 2015 | -7.06 Million USD | 18.51% |
| 2014 | -8.66 Million USD | -31.52% |
| 2013 | -6.59 Million USD | -8.36% |
| 2012 | -6.08 Million USD | 5.41% |
| 2011 | -6.42 Million USD | -30.15% |
| 2010 | -4.93 Million USD | -75.19% |
| 2009 | -2.81 Million USD | -0.99% |
| 2008 | -2.79 Million USD | 9.43% |
| 2007 | -3.08 Million USD | -18.76% |
| 2006 | -2.59 Million USD | -3832.81% |
| 2005 | -66 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -2.03 Million USD | 44.74% |
| 2024 Q4 | -2.39 Million USD | -25.31% |
| 2024 Q3 | -1.9 Million USD | 12.65% |
| 2024 Q2 | -2.18 Million USD | -7.54% |
| 2023 Q3 | -1.81 Million USD | 1.27% |
| 2023 Q4 | -3.67 Million USD | -103.03% |
| 2023 Q2 | -1.83 Million USD | -13.04% |
| 2023 Q1 | -1.62 Million USD | 9.51% |
| 2023 FY | -8.94 Million USD | -10.23% |
| 2022 Q1 | -2.61 Million USD | -25.94% |
| 2022 FY | -8.11 Million USD | 7.21% |
| 2022 Q4 | -1.79 Million USD | -0.27% |
| 2022 Q2 | -1.92 Million USD | 26.48% |
| 2022 Q3 | -1.78 Million USD | 6.91% |
| 2021 Q2 | -2.29 Million USD | -0.95% |
| 2021 Q3 | -2.1 Million USD | 8.05% |
| 2021 Q1 | -2.27 Million USD | -23.94% |
| 2021 Q4 | -2.07 Million USD | 1.58% |
| 2021 FY | -8.74 Million USD | -9.35% |
| 2020 Q4 | -1.83 Million USD | 27.95% |
| 2020 FY | -7.99 Million USD | 7.66% |
| 2020 Q1 | -1.98 Million USD | 8.33% |
| 2020 Q2 | -1.63 Million USD | 17.78% |
| 2020 Q3 | -2.54 Million USD | -55.55% |
| 2019 Q2 | -2.36 Million USD | -16.19% |
| 2019 Q3 | -2.08 Million USD | 12.08% |
| 2019 FY | -8.65 Million USD | 7.14% |
| 2019 Q4 | -2.16 Million USD | -4.11% |
| 2019 Q1 | -2.03 Million USD | 10.67% |
| 2018 FY | -9.32 Million USD | 2.87% |
| 2018 Q4 | -2.28 Million USD | 5.61% |
| 2018 Q3 | -2.41 Million USD | -1.02% |
| 2018 Q2 | -2.39 Million USD | -7.32% |
| 2018 Q1 | -2.23 Million USD | 0.73% |
| 2017 Q4 | -2.24 Million USD | 14.1% |
| 2017 FY | -9.6 Million USD | -8.37% |
| 2017 Q1 | -2.44 Million USD | 2.22% |
| 2017 Q2 | -2.29 Million USD | 5.85% |
| 2017 Q3 | -2.61 Million USD | -13.84% |
| 2016 Q3 | -2.04 Million USD | 2.01% |
| 2016 Q2 | -2.09 Million USD | 6.06% |
| 2016 FY | -8.85 Million USD | -25.43% |
| 2016 Q4 | -2.49 Million USD | -21.86% |
| 2016 Q1 | -2.22 Million USD | 8.68% |
| 2015 Q4 | -2.43 Million USD | -117.05% |
| 2015 Q2 | -1.81 Million USD | -7.68% |
| 2015 FY | -7.06 Million USD | 18.51% |
| 2015 Q3 | -1.12 Million USD | 38.2% |
| 2015 Q1 | -1.68 Million USD | 55.53% |
| 2014 Q3 | -1.23 Million USD | 29.58% |
| 2014 FY | -8.66 Million USD | -31.52% |
| 2014 Q4 | -3.79 Million USD | -207.6% |
| 2014 Q2 | -1.75 Million USD | 7.27% |
| 2014 Q1 | -1.88 Million USD | -20.88% |
| 2013 Q2 | -1.24 Million USD | 21.83% |
| 2013 Q4 | -1.56 Million USD | 28.67% |
| 2013 Q3 | -2.19 Million USD | -76.15% |
| 2013 FY | -6.59 Million USD | -8.36% |
| 2013 Q1 | -1.59 Million USD | -2.83% |
| 2012 Q1 | -1.14 Million USD | 9.6% |
| 2012 FY | -6.08 Million USD | 5.41% |
| 2012 Q4 | -1.54 Million USD | 25.5% |
| 2012 Q3 | -2.07 Million USD | -55.32% |
| 2012 Q2 | -1.33 Million USD | -17.24% |
| 2011 Q3 | -2.55 Million USD | -70.63% |
| 2011 Q1 | -1.11 Million USD | -29.8% |
| 2011 FY | -6.42 Million USD | -30.15% |
| 2011 Q2 | -1.49 Million USD | -34.87% |
| 2011 Q4 | -1.26 Million USD | 50.68% |
| 2010 Q1 | -732.05 Thousand USD | -16.87% |
| 2010 Q4 | -856.18 Thousand USD | 64.7% |
| 2010 Q3 | -2.42 Million USD | -161.73% |
| 2010 Q2 | -926.56 Thousand USD | -26.57% |
| 2010 FY | -4.93 Million USD | -75.19% |
| 2009 Q2 | -644.5 Thousand USD | 14.84% |
| 2009 Q4 | -626.36 Thousand USD | 20.92% |
| 2009 Q1 | -756.83 Thousand USD | 24.23% |
| 2009 FY | -2.81 Million USD | -0.99% |
| 2009 Q3 | -792.02 Thousand USD | -22.89% |
| 2008 Q3 | -805.31 Thousand USD | -98.75% |
| 2008 Q2 | -405.19 Thousand USD | 30.46% |
| 2008 FY | -2.79 Million USD | 9.43% |
| 2008 Q4 | -998.88 Thousand USD | -24.04% |
| 2008 Q1 | -582.64 Thousand USD | 24.81% |
| 2007 FY | -3.08 Million USD | -18.76% |
| 2007 Q2 | -706.64 Thousand USD | -5.0% |
| 2007 Q3 | -928.36 Thousand USD | -31.38% |
| 2007 Q4 | -774.91 Thousand USD | 16.53% |
| 2007 Q1 | -672.99 Thousand USD | 39.91% |
| 2006 Q4 | -1.11 Million USD | -42.05% |
| 2006 FY | -2.59 Million USD | -3832.81% |
| 2006 Q3 | -788.37 Thousand USD | 14.23% |
| 2006 Q2 | -919.12 Thousand USD | -101.11% |
| 2006 Q1 | -457.03 Thousand USD | 0.0% |
| 2005 FY | -66 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.91 Million USD | 73.317% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | 10.526% |
| Armata Pharmaceuticals, Inc. | -40.89 Million USD | 79.173% |
| Actinium Pharmaceuticals, Inc. | -51.92 Million USD | 83.598% |
| Azitra, Inc. | -7.61 Million USD | -11.813% |
| Can-Fite BioPharma Ltd. | -8.19 Million USD | -3.918% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -24.1% |
| Calidi Biotherapeutics, Inc. | -28.99 Million USD | 70.626% |
| CEL-SCI Corporation | -31.47 Million USD | 72.944% |
| iBio, Inc. | -16.63 Million USD | 48.803% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 65.568% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | 57.804% |
| Matinas BioPharma Holdings, Inc. | -23.76 Million USD | 64.167% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | 39.391% |
| NovaBay Pharmaceuticals, Inc. | -5 Million USD | -70.22% |
| Oragenics, Inc. | -20.9 Million USD | 59.263% |
| BiomX Inc. | -27.68 Million USD | 69.239% |
| BiomX Inc. | -27.68 Million USD | 69.239% |
| Protalix BioTherapeutics, Inc. | 10.46 Million USD | 181.416% |
| Palatin Technologies, Inc. | -22.49 Million USD | 62.144% |
| Scorpius Holdings, Inc. | -42.03 Million USD | 79.739% |
| Theriva Biologics, Inc. | -21.43 Million USD | 60.263% |